Ensuring Patient Access to Critical Breakthrough Products Act: Overview, Importance, and Impact

Main Subject: Health

Committee
Sep. 17 2025	Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 37 - 3. Committee Consideration and Mark-up Session Held

IntroReferral

Sep. 15
2025

Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

IntroReferral
Sep. 15 2025	Introduced in House Introduced in House